Amy M Schell, MD
Clinical Focus
Practice Locations
Lexington, KY 40503
Education
University of Kentucky College of Medicine
FellowshipDartmouth-Hitchcock Medical Center
ResidencyDartmouth-Hitchcock Medical Center
FellowshipWashington University
Board Certifications
American Board of Internal Medicine
HematologyAmerican Board of Internal Medicine
Hospital Affiliations
- Baptist Health Richmond
- Baptist Health Lexington
Philosophy of Care
Research
-
Breast Cancer (WIRB-22-0127)
TOL2506A-EXT: Open-label, Safety Extension Study for Subjects with Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study.
Trial Details -
Breast Cancer
TOL2506A: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor Positive
Trial Details -
Breast Cancer (WIRB-22-0111)
Tropion 02: A Phase 3, Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02).
Trial Details -
ER-Positive HER2-Negative Breast Cancer
Serena 4: A Randomized, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Trial Details
